TY  - CHAP
M1  - Book, Section
TI  - Streptogramins
A1  - Gruenberg, Katherine
A1  - Guglielmo, B. Joseph
A2  - Papadakis, Maxine A.
A2  - McPhee, Stephen J.
A2  - Rabow, Michael W.
A2  - McQuaid, Kenneth R.
Y1  - 2023
N1  - 
T2  - Current Medical Diagnosis & Treatment 2023
AB  - Synercid,  the  one  approved  streptogramin,  is  a  combination  of  two  synthetic  derivatives  of  pristinamycin—quinupristin  and  dalfopristin—in  a  30:70  ratio  that  is  administered  intravenously.  It  is  bactericidal  and  inhibits  protein  synthesis  by  binding  to  bacterial  ribosomes.  Its  major  clinical  use  is  in  the  therapy  of  gram-positive  infections,  particularly  methicillin-resistant  S  aureus  and  S  epidermidis  and  enterococci,  including  vancomycin-resistant  E  faecium.  The  combination  is  not  reliably  active  against  E  faecalis.  The  recommended  dose  is  7.5  mg/kg/dose  intravenously  every  8  hours.  In  addition  to  phlebitis  with  peripheral  administration,  the  major  adverse  effects  are  arthralgias  and  myalgias,  which  resolve  with  discontinuation  of  the  medication.  It  is  primarily  cleared  via  the  liver;  streptogramins  inhibit  the  cytochrome  P450  system,  resulting  in  increased  levels  of  cyclosporine  and  other  agents.  With  the  availability  of  linezolid,  daptomycin,  and  other  agents,  the  indications  for  this  agent  are  extremely  limited.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/18
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1193122178
ER  -